Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective
- PMID: 15657666
- DOI: 10.1007/s10350-004-0760-3
Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective
Abstract
Purpose: Fecal incontinence caused by a weak or disrupted internal anal sphincter is common but there has been no effective treatment. This prospective study evaluates the medium-term clinical effects of an injectable silicone biomaterial, PTP (Bioplastique), used to augment the internal anal sphincter.
Method: Eighty-two patients (64 females; median age, 66 years) with severe fecal incontinence and a low anal resting pressure caused by internal anal sphincter dysfunction (defect, n = 11; intact, n = 71) were randomized to PTP injection into intersphincteric space and internal anal sphincter with (Group A, n = 42) or without (Group B, n = 40) guidance by endoanal ultrasound. Both groups were similar in terms of age, gender, past anorectal surgery, duration of follow-up (median, 6 months; range, 1-12 months), and baseline continence score. Sixty-two percent of Group A and 55 percent of Group B had prolonged pudendal nerve terminal motor latency.
Results: There was no significant complication. Two patients in Group A and four patients in Group B noted minor discomfort at injection sites. At one month postprocedure, endoanal ultrasound confirmed retention of silicone biomaterial without migration. In both groups, fecal continence was significantly improved by PTP implants 1 month after injection, but continued to improve significantly for up to 12 months in Group A and 6 months in Group B (P < 0.001). Improvement in fecal continence and maximum anal resting pressure was significantly greater in Group A, in whom injection was guided by endoanal ultrasound, than in Group B. At three months after injection, significantly more Group A patients than Group B patients achieved >50 percent improvement in Wexner's continence score (69 percent vs. 40 percent; P = 0.014). Ninety-three percent of Group A and 92 percent of Group B had >50 percent improvement in global quality of life scores (visual analog scale). At a median follow-up of 6 months, all domains of the fecal incontinence quality of life scale improved significantly in both groups; however, the physical function and mental health scores of Short Form-12 only improved in Group A. A prolonged pudendal nerve terminal motor latency had no effect on functional outcome in either group.
Conclusion: Injection of silicone biomaterial provided a marked improvement in fecal continence and quality of life in patients with internal sphincter dysfunction, despite the presence of pudendal neuropathy.
Similar articles
-
Injectable silicone biomaterial (PTQ) is more effective than carbon-coated beads (Durasphere) in treating passive faecal incontinence--a randomized trial.Colorectal Dis. 2009 May;11(4):382-9. doi: 10.1111/j.1463-1318.2008.01634.x. Epub 2008 Jul 15. Colorectal Dis. 2009. PMID: 18637935 Clinical Trial.
-
Sacral nerve stimulation for fecal incontinence: external anal sphincter defect vs. intact anal sphincter.Dis Colon Rectum. 2008 Jul;51(7):1015-24; discussion 1024-5. doi: 10.1007/s10350-008-9326-0. Epub 2008 May 17. Dis Colon Rectum. 2008. PMID: 18484136
-
Evaluation of the use of PTQ implants for the treatment of incontinent patients due to internal anal sphincter dysfunction.Colorectal Dis. 2008 Jan;10(1):89-94. doi: 10.1111/j.1463-1318.2007.01276.x. Epub 2007 Jun 30. Colorectal Dis. 2008. PMID: 17608753
-
The SECCA procedure: a new therapy for treatment of fecal incontinence.Surg Technol Int. 2004;13:107-10. Surg Technol Int. 2004. PMID: 15744681 Review.
-
Fecal incontinence. Studies on physiology, pathophysiology and surgical treatment.Dan Med Bull. 2003 Aug;50(3):262-82. Dan Med Bull. 2003. PMID: 13677243 Review.
Cited by
-
Treatment of fecal incontinence - review of observational studies (OS) and randomized controlled trials (RCT) related to injection of bulking agent into peri-anal tissue.J Interv Gastroenterol. 2011 Oct;1(4):202-206. doi: 10.4161/jig.1.4.19952. Epub 2011 Oct 1. J Interv Gastroenterol. 2011. PMID: 22586538 Free PMC article.
-
Current management of fecal incontinence: choosing amongst treatment options to optimize outcomes.World J Gastroenterol. 2013 Dec 28;19(48):9216-30. doi: 10.3748/wjg.v19.i48.9216. World J Gastroenterol. 2013. PMID: 24409050 Free PMC article. Review.
-
Towards safer treatments for benign anorectal disease: the pharmacological manipulation of the internal anal sphincter.Ann R Coll Surg Engl. 2007 Sep;89(6):574-9. doi: 10.1308/003588407X205576. Ann R Coll Surg Engl. 2007. PMID: 18201470 Free PMC article.
-
Efficacy and quality of life 2 years after treatment for faecal incontinence with injectable bulking agents.Tech Coloproctol. 2013 Aug;17(4):389-95. doi: 10.1007/s10151-012-0949-8. Epub 2012 Dec 7. Tech Coloproctol. 2013. PMID: 23224913
-
Current management of fecal incontinence.Perm J. 2013 Summer;17(3):65-73. doi: 10.7812/TPP/12-064. Perm J. 2013. PMID: 24355892 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous